A 42-year-old man who abruptly discontinued citalopram (15 mg daily) after one year and rapidly tapered bromazepam (Lexotanil) from approximately 6 mg to 0.25 mg over one week now has a week-long pulsing/oscillating dizziness; what is the most likely diagnosis, what differential diagnoses should be considered, what evaluation (including neurologic and otologic examination, orthostatic vital signs, ECG, laboratory tests, and thyroid function) and red‑flag signs are indicated, and how should his medications be safely managed (including whether to reinstate and taper them)?

Most Likely Diagnosis: Combined SSRI Discontinuation Syndrome and Benzodiazepine Withdrawal

This patient's persistent pulsing/oscillating dizziness is most likely caused by a combination of citalopram discontinuation syndrome and benzodiazepine withdrawal, with the rapid bromazepam taper representing the more dangerous component requiring urgent attention.

The timing (onset within days of medication changes, persisting >1 week), the "pulsing" quality (consistent with the sensory disturbances and "electric shock" sensations characteristic of SSRI discontinuation), and the simultaneous extremely rapid benzodiazepine taper all point to a dual withdrawal syndrome.

Differential Diagnosis Assessment

Primary Culprits (Most Likely)

SSRI Discontinuation Syndrome:

• Citalopram discontinuation syndrome is well-documented and includes dizziness, vertigo, imbalance, and sensory disturbances including paresthesias 1
• The FDA label explicitly warns that abrupt discontinuation causes "dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia" 2
• The "pulsing" sensation described is highly characteristic of SSRI discontinuation—patients frequently report "brain zaps," electric shock sensations, or pulsatile/oscillating feelings 3, 4, 5
• Onset typically occurs within 1-4 days of discontinuation and can persist for 1-2 weeks or longer 4
• Citalopram, as a shorter-acting SSRI, carries moderate risk for discontinuation syndrome 1

Benzodiazepine Withdrawal (Critical Concern):

• The bromazepam taper was dangerously rapid: 6 mg to 0.25 mg over one week after chronic daily use represents an approximately 95% dose reduction in 7 days
• Benzodiazepine withdrawal can cause dizziness, tremor, autonomic instability, anxiety, perceptual disturbances, and—critically—seizures 6, 7
• The CDC guideline explicitly states: "abrupt withdrawal can be associated with rebound anxiety, hallucinations, seizures, delirium tremens, and, in rare cases, death" 6
• Recommended safe tapering is 25% dose reduction every 1-2 weeks, not 95% in one week 6, 7
• Withdrawal symptoms typically emerge within 1-4 days and can persist for weeks
• The combination of abrupt SSRI cessation and rapid benzodiazepine withdrawal likely intensifies symptoms through overlapping mechanisms affecting GABAergic and serotonergic systems

Secondary Considerations (Less Likely but Must Exclude)

Nicotine Withdrawal:

• Can cause irritability, anxiety, difficulty concentrating, but dizziness is not a prominent feature
• Symptoms peak at 2-3 days and substantially improve by 2 weeks
• Given 2 weeks have elapsed, nicotine withdrawal is unlikely to be the primary cause

Vestibular Disorders (BPPV/Vestibular Neuritis):

• BPPV causes episodic positional vertigo, not continuous pulsing dizziness
• Vestibular neuritis causes acute severe vertigo with nystagmus, typically improving over days
• The temporal relationship to medication changes makes this unlikely, but requires examination to exclude

Orthostatic Hypotension:

• Both SSRIs and benzodiazepines can affect blood pressure regulation
• Abrupt citalopram discontinuation has been reported to cause hypertension 8, but orthostatic hypotension is also possible
• Must be assessed with orthostatic vital signs

Anxiety/Hyperventilation:

• Rebound anxiety from both medication withdrawals can cause dizziness
• However, the specific "pulsing" quality suggests more than anxiety alone

Cardiovascular/Arrhythmia:

• Citalopram can prolong QT interval 1
• Withdrawal could theoretically affect cardiac rhythm
• ECG is mandatory to exclude this

Neurological Pathology:

• Stroke, TIA, posterior circulation insufficiency must be excluded
• The bilateral nature and lack of focal deficits make this less likely
• Neurological examination is essential

Required Evaluation NOW

Immediate Assessment (Same-Day)

Neurological Examination:

• Cranial nerves (especially CN VIII, nystagmus)
• Cerebellar testing (finger-to-nose, heel-to-shin, gait, Romberg)
• Motor strength, sensation, reflexes
• Red flags: focal weakness, ataxia, dysarthria, diplopia, severe headache

Otological Examination:

• Dix-Hallpike maneuver for BPPV (though benzodiazepines can suppress findings 9)
• Head impulse test
• Hearing assessment

Vital Signs:

• Orthostatic blood pressure and pulse: supine, sitting, standing at 1 and 3 minutes
• Look for >20 mmHg systolic or >10 mmHg diastolic drop, or pulse increase >30 bpm

Cardiovascular:

• ECG mandatory: assess QTc interval, rhythm, conduction abnormalities
• Auscultation for arrhythmias

Mental Status:

• Assess for confusion, hallucinations, agitation (severe benzodiazepine withdrawal)
• Suicidality screening (SSRI discontinuation risk)

Laboratory Testing (Urgent)

• Complete blood count (anemia)
• Comprehensive metabolic panel (electrolytes, glucose, renal function)
• Thyroid function (TSH, free T4)
• Consider vitamin B12, folate if dietary concerns

RED FLAGS Requiring Emergency Department Evaluation

Go to ED immediately if any of the following:

• Seizure or seizure-like activity (highest risk from benzodiazepine withdrawal)
• Focal neurological deficit (weakness, numbness, vision changes, speech difficulty)
• Severe or sudden-onset "thunderclap" headache
• Syncope or near-syncope
• Chest pain or palpitations
• Persistent vomiting preventing oral intake
• Inability to walk safely
• Confusion, hallucinations, or delirium
• Rapidly worsening symptoms over hours
• Suicidal ideation

Evidence-Based Management

Immediate Management Decision

Given that approximately 2 weeks have elapsed since discontinuation, the safest approach is to reinstate both medications at low doses and then taper gradually under medical supervision.

The rationale:

1. Benzodiazepine withdrawal carries seizure risk that persists for weeks after rapid taper 6, 7
2. SSRI discontinuation symptoms, while uncomfortable, are typically self-limited but can be severe 2, 3, 4
3. Reinstatement usually resolves symptoms within 24 hours 3
4. The alternative—continuing to "ride out" withdrawal—risks serious complications, particularly seizures

Specific Reinstatement and Tapering Protocol

Citalopram Reinstatement:

• Restart citalopram 10 mg daily (half the previous dose to minimize side effects)
• If symptoms resolve within 24-48 hours, this confirms discontinuation syndrome
• After stabilization (1-2 weeks), begin taper:
  • Reduce by 10% of current dose every 1-2 weeks (not 10 mg—10% of dose)
  • Example: 10 mg → 9 mg → 8 mg → 7 mg, etc.
  • The FDA label recommends "gradual reduction rather than abrupt cessation" 2
  • If symptoms re-emerge, hold at current dose for 2-4 weeks before continuing taper
• Total taper duration: 2-4 months minimum for safe discontinuation

Bromazepam Reinstatement (PRIORITY):

• Restart bromazepam 3 mg daily (approximately 50% of previous dose, divided into 2-3 doses)
• This is critical to prevent seizures
• After stabilization (1-2 weeks), begin taper:
  • Reduce by 25% every 1-2 weeks as per CDC guidelines 6, 7
  • Example: 3 mg → 2.25 mg → 1.7 mg → 1.3 mg → 1 mg → 0.75 mg → 0.5 mg → 0.25 mg → 0.125 mg → stop
  • Never reduce faster than 25% every 1-2 weeks
  • Some patients require even slower tapers (10% every 2-4 weeks)
• Total taper duration: 3-6 months minimum
• Consider switching to longer-acting benzodiazepine (diazepam or clonazepam) for smoother taper

Sequencing:

• Reinstate both medications simultaneously given the dual withdrawal syndrome
• Taper benzodiazepine first or simultaneously with SSRI, not SSRI first
• The CDC guideline notes: "it might be safer and more practical to taper opioids first" when both are present, but emphasizes "greater risks of benzodiazepine withdrawal" 6
• In this case, both can be tapered simultaneously under close supervision

Supervision Requirements

This requires psychiatry or internal medicine supervision:

• Initial evaluation by physician within 24-48 hours
• Weekly follow-up during first month
• Bi-weekly follow-up during taper
• Not appropriate for emergency department unless red flags present
• Not appropriate for self-management given seizure risk

Consider psychiatry referral for:

• Underlying anxiety disorder requiring treatment
• History of difficult medication tapers
• Cognitive behavioral therapy to support benzodiazepine taper (improves success rates 6)
• Alternative anxiety treatments (SSRIs other than citalopram, buspirone, etc.)

Supportive Measures

• Avoid alcohol (lowers seizure threshold)
• Avoid driving until symptoms resolve (dizziness risk)
• Adequate hydration and nutrition
• Sleep hygiene (withdrawal disrupts sleep)
• Gradual return to exercise (swimming is fine if supervised and symptoms allow)
• Fall precautions at home

Alternative Management (If Reinstatement Refused)

If the patient adamantly refuses reinstatement:

• Close monitoring for seizures is mandatory
• Consider prophylactic anticonvulsant (discuss with neurology)
• Symptomatic treatment: meclizine for dizziness (though limited evidence 9)
• This is a higher-risk approach and requires explicit informed consent
• Daily check-ins for first week, then every 2-3 days for 4 weeks
• Lower threshold for ED evaluation if any concerning symptoms

Key Clinical Pitfalls to Avoid

1. Do not dismiss this as "just anxiety"—benzodiazepine withdrawal can cause seizures and death
2. Do not continue the current course without intervention—2 weeks is not sufficient time to declare withdrawal "complete"
3. Do not restart at full previous doses—this increases side effect risk
4. Do not taper SSRIs by fixed dose amounts—taper by percentage of current dose
5. Do not taper benzodiazepines faster than 25% every 1-2 weeks
6. Do not assume symptoms will resolve spontaneously—protracted withdrawal syndromes occur
7. Do not overlook cardiovascular or neurological red flags—maintain high index of suspicion